美國至8月14日當週EIA精煉廠設備利用率 97.2%，前值96.2%。

PBOC did not conduct reverse repo operations today; CNY 327.4 bln of overnight reverse repos matured, leaving a net liquidity withdrawal of CNY 327.4 bln.

China’s National Medical Products Administration approved two new drugs: 1) Anfuliqita monoclonal antibody injection (subcutaneous), marketed as Yisaina, from Sansheng Guojian Pharmaceutical (Shanghai) Co., Ltd., for acute gouty arthritis in adults who are contraindicated, intolerant of, or unresponsive to NSAIDs and/or colchicine, or who are unsuitable for repeated steroid use. 2) Fumarate likangkepan capsules, marketed as HengYouDa, from Chengdu Shengdi Pharmaceutical Co., Ltd., approved under the NMPA’s priority review for treatment of adult paroxysmal nocturnal hemoglobinuria (PNH) patients not previously treated with complement inhibitors.